Cycle Pharmaceuticals Enters Exclusive U.S. Deal With Handa To Launch FDA-Approved Leukemia Drug PHYRAGO In September 2025

Cycle Pharmaceuticals (Cycle Pharma) has entered into an exclusive U.S. commercialization agreement with Handa Therapeutics, LLC (Handa), for PHYRAGO, an FDA approved drug for treating two types of leukemia, Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). PHYRAGO will be Cycle Pharma's first oncology product (its ninth commercial product) and will see the company extend its expertise in caring for patients living with chronic conditions into oncology.

PHYRAGO is a novel formulation of Sprycel® (dasatinib) that allows concomitant use with proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs),1 which can directly benefit patients on dasatinib therapy who are prescribed both medications.2

With Sprycel®, the drug exposure of dasatinib can be significantly reduced by more than 40% and 60% when administered with PPIs and H2RAs, respectively.3 In contrast, with PHYRAGO, no clinically significant reduction in the bioavailability of dasatinib was observed following concomitant use with PPIs or H2RAs.1

Handa will be working closely with Cycle Pharma to launch PHYRAGO in September 2025. PHYRAGO will be launched with best-in-class patient support from Cycle Vita™, providing individualized product, educational, and financial assistance* to adult patients with Ph+ CML and Ph+ ALL.